

RealRate

PHARMACEUTICAL 2020

Dianthus Therapeutics Inc. DE Rank 80 of 358





🕝 magenta



PHARMACEUTICAL 2020





Dianthus Therapeutics Inc. DE Rank 80 of 358

The relative strengths and weaknesses of Dianthus Therapeutics Inc. DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dianthus Therapeutics Inc. DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 93% points. The greatest weakness of Dianthus Therapeutics Inc. DE is the variable Research and Development, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 183%, being 146% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	149,843
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,115
Liabilities, Non-Current	0
Other Assets	1,780
Other Compr. Net Income	16
Other Expenses	0
Other Liabilities	6,206
Other Net Income	0
Other Revenues	6,200
Property and Equipment	9,891
Research and Development	59,208
Selling, General and Administrative Expense	23,761

Output Variable	Value in 1000 USD
Assets	161,514
Liabilities	20,321
Expenses	82,969
Revenues	6,200
Stockholders Equity	141,193
Net Income	-76,769
Comprehensive Net Income	-76,761
Economic Capital Ratio	183%

